RT Journal Article
T1 Extracellular tumor-related mRNA in plasma of lymphoma patients and survival implications.
A1 García, Vanesa
A1 García, José Miguel
A1 Silva, Javier
A1 Martín, Paloma
A1 Peña, Cristina
A1 Domínguez, Gemma
A1 Díaz, Raquel
A1 Herrera, Mercedes
A1 Maximiano, Constanza
A1 Sabin, Pilar
A1 Rueda Domínguez, Antonio
A1 Cruz, Miguel Ángel
A1 Rodríguez, José
A1 Canales, Miguel Ángel
A1 Bonilla, Félix
A1 Provencio, Mariano
K1 Espacio Extracelular
K1 Inmunohistoquímica
K1 Estimación de Kaplan-Meier
K1 Linfoma de Células B Grandes Difuso
K1 Células Neoplásicas Circulantes
K1 ARN Mensajero
K1 ARN Neoplásico
K1 Factores de riesgo
K1 Supervivencia sin Enfermedad
AB BACKGROUNDWe studied anomalous extracellular mRNAs in plasma from patients with diffuse large B-cell lymphoma (DLBCL) and their survival implications. mRNAs studied have been reported in the literature as markers of poor (BCL2, CCND2, MYC) and favorable outcome (LMO2, BCL6, FN1) in tumors. These markers were also analyzed in lymphoma tissues to test possible associations with their presence in plasma.METHODOLOGY/PRINCIPAL FINDINGSmRNA from 42 plasma samples and 12 tumors from patients with DLBCL was analyzed by real-time PCR. Samples post-treatment were studied. The immunohistochemistry of BCL2 and BCL6 was defined. Presence of circulating tumor cells was determined by analyzing the clonality of the immunoglobulin heavy-chain genes by PCR. In DLBCL, MYC mRNA was associated with short overall survival. mRNA targets with unfavorable outcome in tumors were associated with characteristics indicative of poor prognosis, with partial treatment response and with short progression-free survival in patients with complete response. In patients with low IPI score, unfavorable mRNA targets were related to shorter overall survival, partial response, high LDH levels and death. mRNA disappeared in post-treatment samples of patients with complete response, and persisted in those with partial response or death. No associations were found between circulating tumor cells and plasma mRNA. Absence of BCL6 protein in tumors was associated with presence of unfavorable plasma mRNA.CONCLUSIONS/SIGNIFICANCEThrough a non-invasive procedure, tumor-derived mRNAs can be obtained in plasma. mRNA detected in plasma did not proceed from circulating tumor cells. In our study, unfavorable targets in plasma were associated with poor prognosis in B-cell lymphomas, mainly MYC mRNA. Moreover, the unfavorable targets in plasma could help us to classify patients with poor outcome within the good prognosis group according to IPI.
PB Public Library of Science
YR 2009
FD 2009-12-15
LK http://hdl.handle.net/10668/621
UL http://hdl.handle.net/10668/621
LA en
NO García V, García JM, Silva J, Martín P, Peña C, Domínguez G, et al. Extracellular tumor-related mRNA in plasma of lymphoma patients and survival implications. PLoS ONE; 4(12):e8173
NO Journal Article; Research Support, Non-U.S. Gov't;
DS RISalud
RD Apr 21, 2025